Exact Mass: 317.09309859999996
Exact Mass Matches: 317.09309859999996
Found 70 metabolites which its exact mass value is equals to given mass value 317.09309859999996,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
N2-Monodes-methylnizatidine
N2-Monodes-methylnizatidine is a metabolite of nizatidine. Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid. (Wikipedia)
N-2-Mdmn
2-{2-[4-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]hydrazono}-2-(methylsulfonyl)acetonitrile
Methyl 2-cyano-3-(2-morpholino-5-nitrophenyl)acrylate
9(10H)-Acridinone, 1,4,5-trihydroxy-3,6-dimethoxy-10-methyl-
1, 3, 5-trihydroxy-2, 4-dimethoxy-10-methyl-10H-acridin-9-one|citruscridone
2,3-Dimethoxy-10-methyl-1,5,6-trihydroxyacridin-9(10H)-one
1,3,6-trihydroxy-4,5-dimethoxy-10-methylacridin-9-one
5,6-Dihydro-8,9-dimethoxypyrrolo[2,1-a]isoquinoline-2,3-dicarboxylic acid
2-quinolin-2-yl-1-[4-(trifluoromethyl)phenyl]ethanol
C18H14F3NO (317.10274300000003)
5-[(3,5-dimethoxybenzoyl)amino]-2-hydroxybenzoic acid
1-(4-(4-Nitro-3-(trifluoromethyl)phenyl)piperazin-1-yl)ethanone
C13H14F3N3O3 (317.09872100000007)
2-quinolin-4-yl-1-[4-(trifluoromethyl)phenyl]ethanol
C18H14F3NO (317.10274300000003)
Methyl 4-(4-(Bis(2-Chloroethyl)Amino)Phenyl)Butyrate
Benzoic acid, 4-[(3,5-dimethoxybenzoyl)amino]-2-hydroxy-
tert-butyl 4-[4-(chloromethyl)-1,3-thiazol-2-yl]piperazine-1-carboxylate
sodium 1-benzyl-5-phenylbarbiturate
C17H14N2NaO3 (317.09020740000005)
2-QUINOLIN-2-YL-1-(3-TRIFLUROMETHYLPHENYL)ETHANOL
C18H14F3NO (317.10274300000003)
6-methoxy-N-(4-methoxyphenyl)quinazolin-4-amine,hydrochloride
C16H16ClN3O2 (317.09309859999996)
N-[(3S)-1-Chloro-5-methyl-2-oxohexan-3-yl]-4-methylbenzene-1-sulfonamide
4-Amino-2-(phenacylthio)-5-pyrimidinecarboxylic acid ethyl ester
2-(2-Deoxy-beta-D-erythro-pentofuranosyl)-7-hydroxypyrimido(1,6-a)benzimidazol-1(2H)-one
4-Sulfonamide-[4-(thiomethylaminobutane)]benzamide
(4-Methylphenyl)-(10-phenothiazinyl)methanone
C20H15NOS (317.08743000000004)
N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)thio]acetamide
1-[4-[2-Nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl]ethanone
C13H14F3N3O3 (317.09872100000007)
2-[[2-furanyl(oxo)methyl]hydrazo]-N-(2-methoxy-5-methylphenyl)-2-oxoacetamide
N-(furan-2-ylmethyl)-N-[(Z)-(2-hydroxy-3-methoxyphenyl)methylideneamino]oxamide
N-[2-[(2Z)-2-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinyl]-2-oxoethyl]furan-2-carboxamide
LY456236
C16H16ClN3O2 (317.09309859999996)
LY456236 is a selective, non-competitive and orally active mGlu1 receptor antagonist that inhibits phosphoinositide hydrolysis with an IC50 of 0.145 μM. LY456236 also inhibits EGFR with an IC50 of 0.91 μM[1][3].
(4ar,7s)-6,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-5-methoxy-4a,7-dihydro-1λ⁴-chromen-1-ylium
atalafoline b
{"Ingredient_id": "HBIN017264","Ingredient_name": "atalafoline b","Alias": "NA","Ingredient_formula": "C16H15NO6","Ingredient_Smile": "CN1C2=C(C=CC(=C2O)OC)C(=O)C3=C1C(=C(C=C3O)OC)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1954","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}